Facebook
Twitter
LinkedIn
Email
 |
Checking for direct PDF access through Ovid | |
Abstract
Adriamycin is an anti-cancer drug which has been recently released by the U. S. Food and Drug Administration to the open market, and its use is increasing in frequency. Unfortunately, when it extravasates into the soft tissues it causes massive tissue necrosis about the site of the attempted intravenous administration. This necrosis develops at a slow rate, continues to increase in severity for several weeks, and does not heal in the usual manner. The resulting ulcers are indolent, and they remain a source of severe pain and functional impairment for many months without healing.
The purpose of this paper is to describe the lesion and our experiences in its treatment.
